Eli Lilly (LLY) 2025 — 56% Revenue From One Molecule

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-12) + Yahoo Finance

Auditor: Ernst & Young LLP — Clean opinion (1 Critical Audit Matter)

One-line verdict: Eli Lilly is the fastest-growing large pharma company in history — revenue nearly doubled from $34.1B to $65.2B in two years, net income quadrupled to $20.6B, and gross margin hit 83%. Three red flags demand investigation: CFFO has trailed net income for three consecutive years (ratio stuck at 0.80-0.83), free cash flow covered less than 50% of net income for three years as $7.8B in CapEx and $17.4B in rebate accruals consumed cash, and cash of $7.3B covers only 17% of $42.5B in debt. The 10-K reveals why: 56% of revenue depends on a single molecule (tirzepatide, marketed as Mounjaro and Zepbound), the company issued $13.2B in new long-term debt in 2025 alone to build 10+ manufacturing facilities, and the government has already selected three Lilly drugs for mandatory Medicare price negotiation. The growth is real. The leverage is also real.

The GLP-1 Juggernaut: One Molecule, $36.5B

Per the 10-K, Lilly operates in "a single business segment — human pharmaceutical products." Revenue by product from the filing:

The filing states: "Revenue increased in 2025 driven primarily by increased volume, partially offset by lower realized prices. The increased volume and lower realized prices in 2025 were primarily driven by Mounjaro and Zepbound."

Tirzepatide — one molecule, two brand names — generated $36.5B in 2025, representing 56% of total revenue. Two years ago it was 16%. Per the filing: "Revenue of Mounjaro increased 53 percent in the U.S., driven by strong demand, partially offset by lower realized prices. Revenue outside of the U.S. was $9.3 billion in 2025 compared to $2.6 billion in 2024."

The U.S. revenue breakdown reveals the pricing pressure: volume grew 53% but prices fell 10%. The 10-K states Zepbound "increased 174 percent in the U.S., driven by increased demand, partially offset by lower realized prices."

Profitability: Pharmaceutical Economics at Peak Form

Per the consolidated statements of operations:

The filing explains gross margin expansion: "Gross margin as a percent of revenue in 2025 increased 1.7 percentage points compared with 2024, primarily driven by favorable product mix and improved cost of production, partially offset by lower realized prices."

Acquired IPR&D of $2.9B represents R&D that Lilly bought rather than developed — the 10-K states this was "primarily related to the acquisitions of Scorpion Therapeutics, Inc.'s PI3K inhibitor program STX-478 and of SiteOne Therapeutics, Inc." These are expensed immediately, depressing net income but not operating cash flow.

Cash Flow: The Three-Year Divergence

Per the consolidated statements of cash flows:

CFFO has been below net income for three consecutive years — our C1 check, a red flag. FCF as a percentage of net income has stayed below 50% for three years — our C2 check, another red flag.

The cash flow statement reveals why. Major adjustments from net income to CFFO:

The dominant cash drain is working capital: $18.3B consumed by receivables, inventory, and prepaid expenses — nearly equal to net income. The auditor's Critical Audit Matter explains the core issue: "At December 31, 2025, the Company had $17,382 million in sales rebate and discount accruals." Pharmaceutical companies bill at list price, then rebate enormous sums to Medicaid, Medicare, and managed care. The auditor flagged the rebate estimation as "especially challenging" due to "the subjectivity of certain assumptions required to estimate the rebate liabilities."

$42.5B in Debt: Betting the Company on GLP-1

Per the balance sheet:

Cash of $7.3B covers only 17% of $42.5B in total debt — our C4 check, the third red flag. Per the cash flow statement, Lilly issued $13.2B in new long-term debt in 2025 (after $11.4B in 2024).

Where is the money going? Property and equipment jumped from $17.1B to $24.7B — a $7.6B increase in one year. The filing describes construction across North Carolina, Wisconsin, Indiana, Virginia, Texas, Alabama, Pennsylvania, Ireland, Germany, and the Netherlands.

With $16.8B in operating cash flow against $0.9B in interest expense, Lilly can service this debt today. But debt/EBITDA of 1.3x with a doubling trajectory warrants monitoring.

The IRA Pricing Threat

From the 10-K risk factors: "In August 2023, HHS selected Jardiance, which is part of our collaboration with Boehringer Ingelheim, as one of the first ten medicines subject to government-set prices in Medicare (effective beginning in 2026) at a significant discount compared to the list price."

The filing continues: "In January 2026, HHS selected Trulicity and Verzenio as additional medicines subject to government-set prices to be effective in 2028. Given our product portfolio, we expect additional products will be selected in future years, which would have the effect of accelerating revenue erosion."

Mounjaro, at $23.0B in revenue, is the largest pharmaceutical product in the world without a generic competitor. It is the most obvious candidate for future Medicare price negotiation. The 10-K warns: "In November 2025, we announced preliminary voluntary agreements with the U.S. government in which, among other arrangements, we agreed to implement measures to lower Medicaid and certain other drug prices for U.S. patients and to launch new medicines with a more balanced pricing approach across developed nations."

Clinical Pipeline: The Insurance Policy

The 10-K's clinical pipeline table lists the next generation:

If orforglipron (oral, submitted to FDA) and retatrutide (Phase 3, met all endpoints) succeed, Lilly's GLP-1 dominance extends well beyond the 2036 tirzepatide patent expiry. If they fail, 56% revenue concentration on tirzepatide becomes existential.

The 18-Point Screening

Beneish M-Score Component Breakdown:

The M-Score of -1.85 sits in the grey zone, driven primarily by the SGI (Sales Growth Index) of 1.447. Beneish's model was calibrated on mature companies. A company growing 45% will mechanically push SGI above alarm thresholds. Combined with the CFFO < NI pattern, this warrants monitoring but does not indicate manipulation — prescription data for Mounjaro and Zepbound is independently trackable.

Key Risks from the 10-K

1. Single-Molecule Concentration

56% of revenue from tirzepatide (Mounjaro + Zepbound). The 10-K warns: "Our results of operations, reputation, or business" could be materially affected by "market uptake of launched products," "intense competition affecting our products, pipeline, or industry," and "dependence on relatively few products or product classes for a significant percentage of our total revenue."

2. Government Price Controls

Per Item 1A: "Public and private actors continue to take aggressive steps to control expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, our medicines." Jardiance faces government-set prices in 2026. Trulicity and Verzenio in 2028. Mounjaro is the obvious next target.

3. Manufacturing Execution Risk

$42.5B in debt, $7.8B in annual CapEx, 10+ facilities under construction. The filing warns of "issues with product supply, regulatory approvals, or other negative outcomes stemming from manufacturing difficulties, disruptions, or shortages." If GLP-1 demand plateaus before the factories are online, the leverage becomes burdensome.

4. Competition

Per the filing: "We face intense competition for qualified individuals" and "our products, pipeline, or industry" face "intense competition." Novo Nordisk's semaglutide (Ozempic/Wegovy) is the direct competitor. The 10-K also warns that "technological innovation has amplified and we expect will continue to amplify competitive aspects of our business."

5. Cash-Pay Market Risk

The 10-K discloses a growing reliance on cash-pay markets: "Patient self-pay sales through LillyDirect represented a growing portion of our business in 2025." The filing warns of "risks related to the level and pace of patient participation in cash-pay markets, which may be influenced by pricing, economic conditions, and competitive offerings."

Key Financial Trends (4-Year)

Summary

Grade: F. Three red flags require investigation before relying on these earnings as reported.

Lilly's underlying business is extraordinary — $65.2B revenue growing 45%, 83% gross margin, $20.6B net income, a clinical pipeline with orforglipron and retatrutide that could extend GLP-1 dominance for a decade. The Altman Z-Score of 4.0 confirms no solvency risk. Ernst & Young issued a clean opinion.

But our screening framework asks whether the reported numbers are trustworthy and sustainable. Three signals say "investigate further":

Important context: These red flags are primarily driven by Lilly's aggressive growth investment, not accounting manipulation. The M-Score of -1.85 is in the grey zone but is mechanically driven by the SGI (growth index). Prescription data for Mounjaro and Zepbound is independently verifiable. The CFFO/NI divergence is explained by the pharmaceutical rebate system and massive CapEx. But context does not eliminate risk — if GLP-1 demand disappoints, $42.5B in debt with 17% cash coverage and 56% revenue concentration on one molecule creates a fragile structure.

Read the 10-K. Read the footnotes on rebate accruals. Then decide.

**Disclaimer**: This report is based on Eli Lilly's fiscal year 2025 10-K filed with the SEC on February 12, 2026. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags using an 18-point forensic framework. Grade F means major red flags were detected that warrant thorough investigation.